Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly crawled date : 2022 - 08 - 08 save search
Global Oncology Drugs Market to Surpass US$ 301.8 Billion by 2030 - Coherent Market Insights
Published: 2022-08-08 (Crawled : 18:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 4.04%
H: 0.0%
C: 0.0%
MCK | $524.83 1.16% -0.05% 650K
|
Distribution Services
|
| O: 0.07%
H: 0.84%
C: 0.12%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.53%
H: 0.49%
C: -0.85%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.51%
H: 1.12%
C: 0.93%
global market
Glioma Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight
Published: 2022-08-08 (Crawled : 16:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
research report trial
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive
Published: 2022-08-08 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: 7.46%
H: 0.63%
C: -18.06%
novartis
Insulin Market Size Worth $111.21 Billion by 2028 at 10.8% CAGR Lead by Biosimilar Insulin Segment (Register 16% CAGR) Global Analysis by The Insight Partners
Published: 2022-08-08 (Crawled : 12:00) - prnewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: -0.62%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
global biosimilar insulin market
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
Published: 2022-08-08 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
taltz injection
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Published: 2022-08-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 2.7%
C: 2.55%
ibi324 macular study diabetic phase 1
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
Published: 2022-08-08 (Crawled : 01:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 3.03%
H: 5.21%
C: -2.59%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.38%
H: 3.38%
C: 1.58%
global cancer study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.